As GSK pursues biotech tie-ups and reinvests in internal R&D capabilities, a "very limited number" of science roles will be eliminated.

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...

Bengaluru: Syngene International has announced the appointment of Chethan Yogesh as the Company Secretary and Compliance ...

Allergy care market grows with rising allergy cases, biologic innovations, and demand for personalized, accessible treatment solutions wor ...

Hyderabad (Telangana) [India], July 10 ... Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...